Search research articles
Contact Us
Filters
Showing results (401-410 of 717) with videos related to
Page
of 72
Sort By:
Plos One
|
April 18, 2013
Increased oxidative stress impairs adipose tissue function in sphingomyelin synthase 1 null mice
Masato Yano, Tadashi Yamamoto, Naotaka Nishimura, et al.
Cardiovascular Intervention and Therapeutics
|
July 30, 2024
Consensus statement on renal denervation by the Joint Committee of Japanese Society of Hypertension (JSH), Japanese Association of Cardiovascular Intervention and Therapeutics (CVIT), and the Japanese Circulation Society (JCS)
Kazuomi Kario, Hisashi Kai, Hiromi Rakugi, et al.
Catheterization and Cardiovascular Interventions : Official Journal of the Society for Cardiac Angiography & Interventions
|
September 9, 2010
PCI using a 4-Fr "child" guide catheter in a "mother" guide catheter: Kyushu KIWAMI® ST registry
Atsushi Hiwatashi, Masashi Iwabuchi, Hiroyoshi Yokoi, et al.
Journal of the American College of Cardiology
|
September 13, 2002
Amelioration of ischemia- and reperfusion-induced myocardial injury by the selective estrogen receptor modulator, raloxifene, in the canine heart
Hisakazu Ogita, Koichi Node, Hiroshi Asanuma, et al.
Cardiovascular Diabetology
|
May 2, 2025
Impact of baseline left ventricular ejection fraction and body mass index on the effect of 24-week Ipragliflozin treatment on left ventricular diastolic function in patients with type 2 diabetes and chronic kidney disease: insights from the PROCEED trial
Hiroki Teragawa, Atsushi Tanaka, Kanae Takahashi, et al.
Cardiovascular Diabetology
|
June 29, 2021
Reduction of estimated fluid volumes following initiation of empagliflozin in patients with type 2 diabetes and cardiovascular disease: a secondary analysis of the placebo-controlled, randomized EMBLEM trial
Atsushi Tanaka, Michio Shimabukuro, Hiroki Teragawa, et al.
Cardiovascular Diabetology
|
August 1, 2021
Comparison of the clinical effect of empagliflozin on glycemic and non-glycemic parameters in Japanese patients with type 2 diabetes and cardiovascular disease treated with or without baseline metformin
Atsushi Tanaka, Michio Shimabukuro, Hiroki Teragawa, et al.
Atherosclerosis
|
April 26, 2008
Lipocalin-type prostaglandin D synthase is a powerful biomarker for severity of stable coronary artery disease
Teruo Inoue, Yutaka Eguchi, Tetsuya Matsumoto, et al.
Circulation Reports
|
July 21, 2022
Sex Differences in Clinical Outcomes Among Patients With COVID-19 and Cardiovascular Disease - Insights From the CLAVIS-COVID Registry
Shingo Matsumoto, Satoshi Noda, Sho Torii, et al.
Scientific Reports
|
June 14, 2019
Randomized Evaluation of Anagliptin vs Sitagliptin On low-density lipoproteiN cholesterol in diabetes (REASON) Trial: A 52-week, open-label, randomized clinical trial
Takeshi Morimoto, Ichiro Sakuma, Mio Sakuma, et al.
Page
of 72
Search research articles
Search
Showing results (401-410 of 717) with videos related to
Sort By:
Page
of 72
Plos One
|
April 18, 2013
Increased oxidative stress impairs adipose tissue function in sphingomyelin synthase 1 null mice
Masato Yano, Tadashi Yamamoto, Naotaka Nishimura, et al.
Cardiovascular Intervention and Therapeutics
|
July 30, 2024
Consensus statement on renal denervation by the Joint Committee of Japanese Society of Hypertension (JSH), Japanese Association of Cardiovascular Intervention and Therapeutics (CVIT), and the Japanese Circulation Society (JCS)
Kazuomi Kario, Hisashi Kai, Hiromi Rakugi, et al.
Catheterization and Cardiovascular Interventions : Official Journal of the Society for Cardiac Angiography & Interventions
|
September 9, 2010
PCI using a 4-Fr "child" guide catheter in a "mother" guide catheter: Kyushu KIWAMI® ST registry
Atsushi Hiwatashi, Masashi Iwabuchi, Hiroyoshi Yokoi, et al.
Journal of the American College of Cardiology
|
September 13, 2002
Amelioration of ischemia- and reperfusion-induced myocardial injury by the selective estrogen receptor modulator, raloxifene, in the canine heart
Hisakazu Ogita, Koichi Node, Hiroshi Asanuma, et al.
Cardiovascular Diabetology
|
May 2, 2025
Impact of baseline left ventricular ejection fraction and body mass index on the effect of 24-week Ipragliflozin treatment on left ventricular diastolic function in patients with type 2 diabetes and chronic kidney disease: insights from the PROCEED trial
Hiroki Teragawa, Atsushi Tanaka, Kanae Takahashi, et al.
Cardiovascular Diabetology
|
June 29, 2021
Reduction of estimated fluid volumes following initiation of empagliflozin in patients with type 2 diabetes and cardiovascular disease: a secondary analysis of the placebo-controlled, randomized EMBLEM trial
Atsushi Tanaka, Michio Shimabukuro, Hiroki Teragawa, et al.
Cardiovascular Diabetology
|
August 1, 2021
Comparison of the clinical effect of empagliflozin on glycemic and non-glycemic parameters in Japanese patients with type 2 diabetes and cardiovascular disease treated with or without baseline metformin
Atsushi Tanaka, Michio Shimabukuro, Hiroki Teragawa, et al.
Atherosclerosis
|
April 26, 2008
Lipocalin-type prostaglandin D synthase is a powerful biomarker for severity of stable coronary artery disease
Teruo Inoue, Yutaka Eguchi, Tetsuya Matsumoto, et al.
Circulation Reports
|
July 21, 2022
Sex Differences in Clinical Outcomes Among Patients With COVID-19 and Cardiovascular Disease - Insights From the CLAVIS-COVID Registry
Shingo Matsumoto, Satoshi Noda, Sho Torii, et al.
Scientific Reports
|
June 14, 2019
Randomized Evaluation of Anagliptin vs Sitagliptin On low-density lipoproteiN cholesterol in diabetes (REASON) Trial: A 52-week, open-label, randomized clinical trial
Takeshi Morimoto, Ichiro Sakuma, Mio Sakuma, et al.
Page
of 72